CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $257.29M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.19M
Average 0.10M
CAMP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
CAMP4 Therapeutics CorporationNASDAQ: CAMP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $18.33M (cash outflow) rose 47.4% year over year, behind the +66.7% change in trailing-twelve-month net income. Sequentially, it fell 54.5% from the prior quarter.
Context
- Net income amounted to 2298.5% of revenue in FY2025, down 5644.9 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$34.41M (-57.2%) for the fiscal year ending Dec 2026, a slowdown from the +55.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.33M-54.5% QoQ
- Last fiscal yearDec 2025
- -$80.4M+55.2% YoY
- LTMMar 2026
- -$86.3M+66.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +47.4% | +32.6% | -14.8 pp |
| 1 year | +55.2% | -57.2% | -112.5 pp |
| 3-year CAGR | — | -29.2% | — |
| 5-year CAGR | -24.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (80.4M) USD
- Year-over-year change
- -55.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (80.4M) | -55.2% |
| FY2024 | 2024-12-31 | (51.79M) | -5.1% |
| FY2023 | 2023-12-31 | (49.29M) | -11.5% |
| FY2022 | 2023-02-28 | (44.19M) | -57.9% |
| FY2021 | 2022-02-28 | (27.99M) | — |
Net Income vs competitors
How CAMP compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +66.7% is the 3rd highest of 9, against a peer median of +1.3%.
- Net income amounts to 2193.7% of revenue for CAMP, versus a peer median of 66.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $88.87M USD | -31.7% | -6.3% | — | |
| LTM Mar 2026 | $86.3M USD | +66.7% | — | 2193.7% | |
| LTM Mar 2026 | $78.34M USD | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M USD | -7.7% | +35.7% | — |
| LTM Mar 2026 | $70.03M USD | +10.4% | +17.8% | 36859.5% | |
| LTM Mar 2026 | $44.95M USD | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $39.95M USD | +162.9% | +13.7% | — | |
| LTM Mar 2026 | $37.1M USD | +163.8% | — | 14.5% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$12.18M CAD | -73.6% | +21.9% | 66.4% |
| Peer median (excluding CAMP) | — | +1.3% | +13.7% | 66.4% | |
Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.99M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Depreciation & Amortization | 22.8M | 878K | 1.68M | 1.7M | 1.64M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.32M | 1.38M | 2.91M | 4.03M | 4M |
| Change in Working Capital | 1.59M | 373K | (154K) | (1.88M) | 13.01M |
| Accounts Receivables | 1.44M | 0 | 0 | 0 | 0 |
| Inventory | 5.16M | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | (1.03M) |
| Other Working Capital | (5.01M) | 373K | (154K) | (1.88M) | 14.04M |
| Other Non-Cash Items | (11.94M) | 3.02M | 705K | 2.39M | 32.21M |
| Operating Cash Flow | (4.22M) | (38.54M) | (44.16M) | (45.56M) | (29.55M) |
| Capital Expenditures | (13.3M) | (4.03M) | (678K) | (441K) | (279K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 36K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 5.72M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (7.58M) | (4.03M) | (678K) | (441K) | (243K) |
| Debt Repayment | — | (93K) | 116K | (824K) | (208K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 61.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.64M) | 100.25M | 185K | 72.49M | 14.93M |
| Financing Cash Flow | (2.64M) | 100.16M | 301K | 71.66M | 75.89M |
| Effect of Forex Changes | (965K) | 25.6M | 0 | 0 | 0 |
| Net Change in Cash | (15.4M) | 83.19M | (44.53M) | 25.66M | 46.09M |
| Free Cash Flow | (17.52M) | (42.57M) | (44.83M) | (46M) | (29.83M) |
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
Intrinsic Alpha fair value
Locked
Current Price
$4.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.